Rosai-Dorfman 病市场 - 全球产业规模、份额、趋势、机会和预测，按类型（经典 Rosai-Dorfman 病、结外 Rosai-Dorfman 病）、按手术类型、按最终用户、按地区和竞争进行细分，2020 年至 2030 年预测

2024 年全球罗赛-多夫曼病 (RDD) 市场价值为 6.4705 亿美元，预计到 2030 年将达到 9.6266 亿美元，预测期内的年复合成长率(CAGR) 为 6.82%。这个市场代表了医疗保健行业一个专业但至关重要的领域，专注于罗赛-多夫曼病（一种罕见的非恶性疾病，也称为伴有巨大淋巴结肿大的窦组织细胞增生症 (SHML)）的诊断、治疗和持续研究。

RDD 的特征是组织细胞（一种白血球）过度增殖和积聚，主要发生在淋巴结内，但也可能影响其他组织和器官。儘管其罕见，但全球意识的增强、诊断技术的进步以及对有效治疗策略的追求加速了市场的成长。

关键驱动因素

发病率上升和诊断进展

儘管罗塞-多夫曼病仍然是一种罕见疾病，据估计在美国每 20 万人中就有 1 人患有此病，每年报告的新病例约为 100 例，但诊断能力的提高已导致全球对该疾病的识别率提高。影像技术、组织病理学和分子诊断方面的创新提高了 RDD 诊断的准确性和及时性，从而增加了报告病例的数量并推动了对有针对性的治疗干预的需求。

这种日益增长的认识推动了旨在创造专门诊断工具和治疗方法的研究和开发活动。最近的发现，包括在选定的 RDD 患者中发现 BRAF-V600E 等基因突变，为精准医疗和个人化治疗策略开闢了新的机会。因此，製药公司和医疗保健提供者正在投资专门针对 RDD 的临床和生物学特征的治疗方法。

该市场涵盖广泛的产品，包括诊断检测、影像系统、药物和支持性护理解决方案。製药公司、学术机构和临床服务提供者之间的合作对于推进研究、揭示疾病机制、探索潜在生物标记和开发创新治疗方法至关重要。

主要挑战

疾病盛行率低且认知度有限

市场发展的一大障碍是 RDD 的盛行率极低，加上医疗专业人员的认识有限。由于该疾病的罕见性，常常导致误诊或延迟诊断，因为其临床表现可能与其他更常见的疾病相似。 RDD 可表现出多种症状，从无症状淋巴结肿大到广泛的器官受累，这进一步增加了及时检测的难度。

临床上很少遇到 RDD，导致医生对此普遍不熟悉，从而妨碍了及时准确的诊断。此外，缺乏广泛的认知会影响对 RDD 特定研究的资金和投资，从而限制诊断和治疗创新的进步。这种投资不足对有效、有针对性的干预措施的发展提出了挑战，并阻碍了对该疾病病理生理学的更广泛理解。

主要市场趋势

采用免疫组织化学及分子分析

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球罗赛-多夫曼病市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依类型（经典（结节性）Rosai-Dorfman 病、结外 Rosai-Dorfman 病）
  • 依手术类型（诊断、治疗）
  • 按最终使用者（医院和诊所、门诊护理中心、其他）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美Rosai-Dorfman病市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲Rosai-Dorfman病市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区 Rosai-Dorfman 病市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美罗赛-多夫曼病市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲Rosai-Dorfman病市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章： 大环境分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Koninklijke Philips NV
• GE HealthCare
• Canon Inc
• Siemens Healthineers
• SternMed GmbH
• Jubilant Cadista Pharmaceuticals Inc
• LGM Pharma
• Henan Lihua Pharmaceutical Co., Ltd
• Niksan Pharmaceutical
• Sandoz Canada Inc

第 16 章：策略建议

第17章调查会社について・免责事项

Global Rosai-Dorfman Disease (RDD) market was valued at USD 647.05 million in 2024 and is projected to reach USD 962.66 million by 2030, expanding at a compound annual growth rate (CAGR) of 6.82% over the forecast period. This market represents a specialized yet vital segment of the healthcare industry, focusing on the diagnosis, treatment, and ongoing research of Rosai-Dorfman Disease-a rare, non-malignant disorder also known as sinus histiocytosis with massive lymphadenopathy (SHML).

RDD is characterized by the excessive proliferation and accumulation of histiocytes-a type of white blood cell-primarily within lymph nodes, though it may also affect other tissues and organs. Despite its rarity, growing global awareness, advancements in diagnostic technologies, and the pursuit of effective treatment strategies have accelerated market growth.

Key Drivers

Rising Incidence and Diagnostic Advancements

While Rosai-Dorfman Disease remains an uncommon condition-with an estimated prevalence of 1 in 200,000 individuals and approximately 100 new cases reported annually in the United States-enhanced diagnostic capabilities have led to increased identification of the disease globally. Innovations in imaging techniques, histopathology, and molecular diagnostics have improved the accuracy and timeliness of RDD diagnoses, contributing to a higher reported case volume and driving demand for targeted therapeutic interventions.

This growing recognition has fueled research and development activities aimed at creating specialized diagnostic tools and treatments. Recent discoveries, including the identification of genetic mutations such as BRAF-V600E in select RDD patients, have opened new opportunities for precision medicine and personalized treatment strategies. As a result, pharmaceutical firms and healthcare providers are investing in therapies tailored specifically to the clinical and biological characteristics of RDD.

The market spans a broad range of offerings including diagnostic assays, imaging systems, pharmaceuticals, and supportive care solutions. Collaborative efforts among pharmaceutical companies, academic institutions, and clinical providers are crucial in advancing research, uncovering disease mechanisms, exploring potential biomarkers, and developing innovative treatments.

Key Challenges

Low Disease Prevalence and Limited Awareness

A significant barrier to market development is the exceptionally low prevalence of RDD, compounded by limited awareness among healthcare professionals. The rarity of the condition often leads to misdiagnosis or delayed diagnosis, as its clinical presentation may mimic other, more common diseases. RDD can manifest with a wide spectrum of symptoms, from asymptomatic lymph node enlargement to extensive organ involvement, further complicating timely detection.

Infrequent clinical encounters with RDD contribute to a general unfamiliarity among physicians, hindering prompt and accurate diagnosis. Additionally, the lack of widespread awareness impacts funding and investment in RDD-specific research, limiting advancements in diagnostic and therapeutic innovations. This underinvestment challenges the development of effective, targeted interventions and impedes the broader understanding of the disease's pathophysiology.

Key Market Trends

Adoption of Immunohistochemistry and Molecular Profiling

The market is witnessing a paradigm shift toward precision diagnostics, underscored by the increasing use of immunohistochemistry (IHC) and molecular profiling. These technologies are becoming standard in identifying and confirming RDD cases with greater accuracy. IHC techniques enable the detection of disease-specific protein markers such as S100 and CD68, facilitating differentiation from other histiocytic and lymphoproliferative disorders.

Simultaneously, molecular profiling-through platforms such as next-generation sequencing (NGS)-is uncovering recurrent mutations (e.g., KRAS, MAP2K1) associated with RDD pathogenesis. These insights are paving the way for personalized therapeutic approaches, particularly for patients with refractory or recurrent disease.

As molecular diagnostic tools become more accessible and cost-effective, their adoption is expanding across both developed and emerging healthcare markets. Institutions are integrating these technologies into clinical practice, not only improving diagnostic precision but also enhancing patient monitoring and prognosis assessment.

Key Market Players

• Koninklijke Philips N.V.
• GE HealthCare
• Canon Inc
• Siemens Healthineers
• SternMed GmbH
• Jubilant Cadista Pharmaceuticals Inc
• LGM Pharma
• Henan Lihua Pharmaceutical Co., Ltd
• Niksan Pharmaceutical
• Sandoz Canada Inc

Report Scope:

In this report, the Global Rosai-Dorfman Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Rosai-Dorfman Disease Market, By Type:

• Classic (nodal) Rosai-Dorfman disease
• Extranodal Rosai-Dorfman disease

Global Rosai-Dorfman Disease Market, By Route of Administration:

• Oral
• Parenteral
• Sublingual
• Nasal

Global Rosai-Dorfman Disease Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centres
• Others

Global Rosai-Dorfman Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rosai-Dorfman Disease Market.

Available Customizations:

Global Rosai-Dorfman Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rosai-Dorfman Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Classic (nodal) Rosai-Dorfman disease, Extranodal Rosai-Dorfman disease)
  • 5.2.2. By Procedure Type (Diagnosis, Treatment)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centres, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Rosai-Dorfman Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Procedure Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Rosai-Dorfman Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Procedure Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Rosai-Dorfman Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Procedure Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Rosai-Dorfman Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Procedure Type
      • 6.3.3.2.3. By End User

7. Europe Rosai-Dorfman Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Procedure Type
  • 7.2.3. By End User
  • 7.2.4. By Age Group
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Rosai-Dorfman Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Procedure Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Rosai-Dorfman Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Procedure Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Rosai-Dorfman Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Procedure Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Rosai-Dorfman Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Procedure Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Rosai-Dorfman Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Procedure Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Rosai-Dorfman Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Procedure Type
  • 8.2.3. By End User
  • 8.2.4. By Age Group
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Rosai-Dorfman Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Procedure Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Rosai-Dorfman Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Procedure Type
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Rosai-Dorfman Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Procedure Type
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Rosai-Dorfman Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Procedure Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Rosai-Dorfman Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Procedure Type
      • 8.3.5.2.3. By End User

9. South America Rosai-Dorfman Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Procedure Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Rosai-Dorfman Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Procedure Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Rosai-Dorfman Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Procedure Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Rosai-Dorfman Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Procedure Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Rosai-Dorfman Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Procedure Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Rosai-Dorfman Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Procedure Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Rosai-Dorfman Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Procedure Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Rosai-Dorfman Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Procedure Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Koninklijke Philips N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. GE HealthCare
• 15.3. Canon Inc
• 15.4. Siemens Healthineers
• 15.5. SternMed GmbH
• 15.6. Jubilant Cadista Pharmaceuticals Inc
• 15.7. LGM Pharma
• 15.8. Henan Lihua Pharmaceutical Co., Ltd
• 15.9. Niksan Pharmaceutical
• 15.10. Sandoz Canada Inc

16. Strategic Recommendations

17. About Us & Disclaimer